Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event
Shotaro Ide, Hiroshi Soda, Tomoaki Hakariya, Shinnosuke Takemoto, Hiroshi Ishimoto, Shinya Tomari, Toyomitsu Sawai, Seiji Nagashima, Masataka Furukawa, Yoichi Nakamura, Shigeru Kohno
20100101
2010 Feb 1
Lung Cancer
Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event
Lung Cancer. 2010 Feb;67(2):248-250, Shotaro Ide, Hiroshi Soda, Tomoaki Hakariya, Shinnosuke Takemoto, Hiroshi Ishimoto, Shinya Tomari, Toyomitsu Sawai, Seiji Nagashima, Masataka Furukawa, Yoichi Nakamura, Shigeru Kohno
There has been no literature which reports a case of interstitial lung disease associated with sorafenib. However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib. In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma. Oncologists supervising future clinical trials for lung cancer should...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
